Influenza vaccine

Safe and effective vaccines for all Europeans: useful information and materials

Retrieved on: 
Thursday, January 7, 2021
Medical specialties, Vaccines, Vaccination, Medicine, Vaccine, Virology, Health care, COVID-19 vaccine, Influenza vaccine

Safe and effective vaccines for all Europeans: useful information and materials  

Key Points: 

Safe and effective vaccines for all Europeans: useful information and materials  
​​​​​​​The European Union has secured so far 2 billion doses of potential vaccines, more than enough for protecting us all. In cooperation with other EU institutions, we are sharing useful information on how vaccines work, and how extraordinary their rapid development has and continues to be.

Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine

Retrieved on: 
Tuesday, January 5, 2021
Medical specialties, Health, Medicine, Virology, Vaccines, Vaccination, Vaccine, Influenza vaccine, Virus, Attenuated vaccine, Influenza research

Emergex also has programmes in development for a universal Influenza vaccine and a universal Filovirus vaccine (including viruses such as Ebola and Marburg) and discovery programmes for a Yellow Fever Booster vaccine and a Chikungunya vaccine.

Key Points: 
  • Emergex also has programmes in development for a universal Influenza vaccine and a universal Filovirus vaccine (including viruses such as Ebola and Marburg) and discovery programmes for a Yellow Fever Booster vaccine and a Chikungunya vaccine.
  • The Company also has a collaboration in place with Brazil-based Bio-Manguinhos/Fiocruz for the development of several vaccine candidates, including a potential vaccine for COVID-19.
  • Background to Emergex Vaccine Approach:
    Both nave T-Cells and memory T-Cells are activated in an acute viral infection via trogocytosis (or cross-dressing).
  • It has one of Brazils largest public laboratories for vaccine production - the Immunobiological Technology Institute (Bio-Manguinhos).

Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine

Retrieved on: 
Tuesday, January 5, 2021
Medical specialties, Health, Medicine, Virology, Vaccines, Vaccination, Vaccine, Influenza vaccine, Virus, Attenuated vaccine, Influenza research

Emergex also has programmes in development for a universal Influenza vaccine and a universal Filovirus vaccine (including viruses such as Ebola and Marburg) and discovery programmes for a Yellow Fever Booster vaccine and a Chikungunya vaccine.

Key Points: 
  • Emergex also has programmes in development for a universal Influenza vaccine and a universal Filovirus vaccine (including viruses such as Ebola and Marburg) and discovery programmes for a Yellow Fever Booster vaccine and a Chikungunya vaccine.
  • The Company also has a collaboration in place with Brazil-based Bio-Manguinhos/Fiocruz for the development of several vaccine candidates, including a potential vaccine for COVID-19.
  • Background to Emergex Vaccine Approach:
    Both nave T-Cells and memory T-Cells are activated in an acute viral infection via trogocytosis (or cross-dressing).
  • It has one of Brazils largest public laboratories for vaccine production - the Immunobiological Technology Institute (Bio-Manguinhos).

Global Influenza Vaccine Production and Distribution Market Report 2020:Impact of COVID-19, Vaccine Makeup, Vaccine Effectiveness, and Reimbursement

Retrieved on: 
Thursday, December 31, 2020
Medical specialties, Drugs, Vaccines, Influenza vaccines, Vaccination, Influenza, Influenza vaccine, Vaccine, Live attenuated influenza vaccine, Flu season, Swine flu pandemic vaccine, COVID-19 vaccine

DUBLIN, Dec. 31, 2020 /PRNewswire/ -- The "2020 Influenza Vaccine Production and Distribution Market Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 31, 2020 /PRNewswire/ -- The "2020 Influenza Vaccine Production and Distribution Market Report" report has been added to ResearchAndMarkets.com's offering.
  • The 2020-2021 flu season will be the first full influenza season coinciding with the COVID-19 pandemic, creating concerns of potential coinfections and overwhelmed hospitals.
  • The 2020 HIDA Influenza Vaccine Production & Distribution Market Report provides insights into the upcoming flu season including the impact of COVID-19, vaccine makeup, vaccine effectiveness, and reimbursement.
  • Insights include:
    52% of Americans received a vaccine last season; experts this year target a 70% vaccination rate
    Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

2020 Influenza Vaccine Production and Distribution Market Report - ResearchAndMarkets.com

Retrieved on: 
Monday, December 28, 2020
General Health, Pharmaceutical, Health, Medical specialties, Drugs, Vaccines, Influenza vaccines, Influenza vaccine, Vaccine, Influenza, Live attenuated influenza vaccine, Flu season, Vaccination, Swine flu pandemic vaccine, Global Advisory Committee on Vaccine Safety

The "2020 Influenza Vaccine Production and Distribution Market Report" has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2020 Influenza Vaccine Production and Distribution Market Report" has been added to ResearchAndMarkets.com's offering.
  • The 2020-2021 flu season will be the first full influenza season coinciding with the COVID-19 pandemic, creating concerns of potential coinfections and overwhelmed hospitals.
  • The 2020 HIDA Influenza Vaccine Production & Distribution Market Report provides insights into the upcoming flu season including the impact of COVID-19, vaccine makeup, vaccine effectiveness, and reimbursement.
  • Insights include:
    52% of Americans received a vaccine last season; experts this year target a 70% vaccination rate
    View source version on businesswire.com: https://www.businesswire.com/news/home/20201228005101/en/

Almost 9 Million Blacks Ready To Take the COVID Vaccine

Retrieved on: 
Wednesday, December 23, 2020
Medical specialties, Vaccines, Medicine, Life sciences, Vaccine, Virology, Vaccination, Vaccine hesitancy, Influenza vaccine

BDO has conducted numeroussurveys beginning in April 2020 regarding the willingness of Blacks to take the vaccine.

Key Points: 
  • BDO has conducted numeroussurveys beginning in April 2020 regarding the willingness of Blacks to take the vaccine.
  • The number of Blacks stating they will not take the vaccine has dropped to 42%, a substantial decrease from 60%.
  • "It is now time to be very deliberate to ensure the 8 million Blacks who want the vaccine actually receive the vaccination," states Dr. Reed Tuckson.
  • Based on this latest survey, this approach is having an effect on how Blacks view the vaccine.

Global Pediatric Vaccines Market (2020 to 2025) - Growth, Trends, and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 22, 2020
Health, General Health, Vaccines, Medical specialties, Health care, Medicine, Vaccine, Conjugate vaccine, Pneumococcal conjugate vaccine, Vaccination, Pneumococcal vaccine, Influenza vaccine

These "glycoconjugate" vaccines elicit T-cell help for B-cells that produce IgG antibodies to the conjugated polysaccharide.

Key Points: 
  • These "glycoconjugate" vaccines elicit T-cell help for B-cells that produce IgG antibodies to the conjugated polysaccharide.
  • The North American pediatric vaccine market is expected to register a significant market share.
  • Considering the factors responsible for the large size of the US pediatric vaccines market, the country witnesses the highest percentage of children getting vaccinations.
  • Other vaccines, like chickenpox, pneumococcal conjugate vaccine (PCV), and Combined 7-vaccine series, are received by around 90% of the children.

Guillain-Barré Experts Clarify COVID-19 Vaccine Confusion with Open Letter to Dr. A.S. Fauci

Retrieved on: 
Monday, December 21, 2020
Medical specialties, Medicine, Health, Vaccines, Influenza vaccines, Swine flu pandemic vaccine, Influenza vaccine, Swine influenza, Vaccine, COVID-19 vaccine, Influenza, Anthony Fauci

In response to a recent public statement made by Dr. A.S. Fauci, Director of NIAID, NIH, regarding the COVID-19 vaccine as it pertains to the GBS community, and to further clarify COVID-19 vaccine confusion among patients & caregivers, the following open letter to Dr. A.S.Fauci, has been authored as referenced.

Key Points: 
  • In response to a recent public statement made by Dr. A.S. Fauci, Director of NIAID, NIH, regarding the COVID-19 vaccine as it pertains to the GBS community, and to further clarify COVID-19 vaccine confusion among patients & caregivers, the following open letter to Dr. A.S.Fauci, has been authored as referenced.
  • "On the television show, you stated that people who had GBS in the past should avoid the COVID vaccines as they may cause another episode of GBS.
  • GBS was associated with the 1976/1977 swine flu vaccine at a rate of about 1 case/100,000 vaccinees.
  • In fact, the CDC recommends that everyone get the flu vaccine as the benefits of the vaccine outweigh the risks of GBS ( https://www.cdc.gov/vaccinesafety/concerns/guillain-barre-syndrome.html ).

Announcing ArmorVax, the Future of Vaccine Processing and Reporting

Retrieved on: 
Monday, December 21, 2020
Medical specialties, Vaccination, Virology, Medicine, Life sciences, Biotechnology, Vaccine, Vaccines, Medical research, Vaccination schedule, Influenza vaccine

RB Medical Supply continues its mission to meet the needs of everyone affected by the pandemic with its newest product, "ArmorVax."

Key Points: 
  • RB Medical Supply continues its mission to meet the needs of everyone affected by the pandemic with its newest product, "ArmorVax."
  • This new healthcare technology aims to connect patients to vaccine providers and streamline the immunization process.
  • The ArmorVax mobile vaccine app offers consumers the ability to find a vaccine provider and schedule an appointment at a time and location most convenient for them while keeping their vaccination records at their fingertips.
  • The vaccine app and consumer website are on track to launch for full public use by Dec.25, 2020.

Medly Pharmacy, EmblemHealth, NYC Housing Authority, and NYPD PSA 7 Team Up for Toy Giveaway and Flu Shot Event

Retrieved on: 
Saturday, December 19, 2020
Medical specialties, Infectious diseases, Medicine, Influenza, Influenza vaccine, Vaccines, Social distancing, Flu season

NYPD will block off Melrose Avenue so that safe social distancing measures can be maintained, and masks will be mandatory.

Key Points: 
  • NYPD will block off Melrose Avenue so that safe social distancing measures can be maintained, and masks will be mandatory.
  • This is not the first time Medly and EmblemHealth have taken a stand in their local communities to address disadvantaged residents.
  • The partners put on three successful flu vaccination events targeting underserved populations during this flu season.
  • More information about the event is as follow:
    Toy giveaway: Tickets for the toy giveaway will be distributed by PSA 7.